Strengthening your employer brand through thought leadership is valuable for several reasons. Firstly, it will allow your organisation to establish itself as a trusted authority in the life science industry. You can position your company as a go-to source for industry knowledge and expertise by consistently sharing valuable insights, research findings, and thought-provoking content. This enhances your reputation and builds credibility and trust amongst potential candidates, employees, patients, and other stakeholders.
PharmiWeb Recruiter Blog
AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
- Evinova will operate as a separate health-tech business within AstraZeneca
- Evinova’s globally-scaled digital health solutions are evidence-led, science-based and human experience-driven to serve clinical trial sponsors, clinical research organisations (CROs), clinical trial site care teams and patients
- First strategic collaborations with globally-leading CROs Parexel and Fortrea enable Evinova’s digital health solutions to be offered to their wide customer base
AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector.
-- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas --
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark
Bagsværd, Denmark, 10 November 2023 – Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases.
As a recruitment professional in the life science industry, employee referral programs (ERPs) are a highly effective way of expanding your talent pool, identifying high-quality candidates, and engaging both active and passive talent.
The Global Talent Lab, in partnership with XTX Markets and the UK Department for Science, Innovation, and Technology (DSIT), proudly introduces the BIG UK Programme. This initiative is designed to identify and nurture global talent, positioning them to push the boundaries in mathematics, science, and AI.
As a recruiter or hiring manager in the life science industry, it’s crucial to remain objective and impartial during the hiring process to build a diverse and inclusive workforce that brings together a wide range of perspectives and experiences. Biases in the hiring process, whether conscious or not, all too often lead to talented candidates being overlooked, and missing out on opportunities that should be equal for all.
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, now presents itself with a new corporate branding that is designed to inspire deeper connection with the company’s diverse customers, partners, and employees.
- New partnership will harness Moderna's mRNA rapid-response platform, clinically validated during the COVID-19 pandemic, to accelerate epidemic and pandemic vaccine development
- First project will enable rapid pre-clinical testing of antigen designs for high-risk viral families, to advance global outbreak readiness
CAMBRIDGE, MA / ACCESSWIRE / October 30, 2023 / The Coalition for Epidemic Preparedness Innovations (CEPI) and Moderna, Inc. (NASDAQ:MRNA) have entered into a strategic partnership that will harness Moderna's mRNA platform to accelerate the development of vaccines against viral disease outbreaks that threaten global health. The work undertaken as part of this partnership could expand the infectious disease targets for mRNA vaccine technology and strengthen pandemic preparedness and public health efforts in alignment with the 100 Days Mission, a global goal to compress vaccine development timelines to 100 days.
CAMBRIDGE, MA / ACCESSWIRE / October 26, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.